Versant Venture Capital VI Reports Dilution-Driven Decrease in Ownership Percentage of Tempest Therapeutics

Versant Venture Capital VI, L.P., along with several affiliated entities (collectively the 'Reporting Persons'), filed an Amendment No. 7 to their Schedule 13D regarding their holdings in Tempest Therapeutics, Inc. (TPST). The filing, dated April 2, 2026, reports that Versant Venture Capital VI, L.P. holds 16,149 shares of Common Stock, representing approximately 0.1% of the class. The primary purpose of this amendment is to reflect a decrease of over 1% in the aggregate percentage ownership of the Reporting Persons. This decrease was not due to the sale of shares by the filers, but rather resulted from dilution caused by the Issuer's sales of additional Common Stock since the previous filing (Amendment No. 6). Other affiliated entities, including Versant Vantage II, L.P. and Versant Venture Capital IV, L.P., hold 162,972 shares (1.1%) and 90,084 shares (0.6%) respectively. The total ownership percentage is calculated based on 14,344,034 shares outstanding as of March 25, 2026.